-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Discussant on Newly Diagnosed Acute Myeloid Leukemia

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium: Something Old, Something New - Recent Immunotherapy and Targeted Agent Approvals
Monday, December 12, 2022, 10:30 AM-12:00 PM

Ehab L. Atallah, MD

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

Disclosures: Atallah: Blueprint: Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Takeda: Research Funding; BMS: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding; Servier: Consultancy.

See more of: ASH-FDA Joint Symposium: Something Old, Something New - Recent Immunotherapy and Targeted Agent Approvals
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>